297 related articles for article (PubMed ID: 9023127)
21. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.
Ingelman-Sundberg M; Sim SC
Biochem Biophys Res Commun; 2010 May; 396(1):90-4. PubMed ID: 20494117
[TBL] [Abstract][Full Text] [Related]
22. Genetic basis of drug metabolism.
Ma MK; Woo MH; McLeod HL
Am J Health Syst Pharm; 2002 Nov; 59(21):2061-9. PubMed ID: 12434718
[TBL] [Abstract][Full Text] [Related]
23. Clinical Utility and Economic Impact of CYP2D6 Genotyping.
Reynolds KK; McNally BA; Linder MW
Clin Lab Med; 2016 Sep; 36(3):525-42. PubMed ID: 27514466
[TBL] [Abstract][Full Text] [Related]
24. Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens.
Kehinde O; Ramsey LB; Gaedigk A; Oni-Orisan A
Clin Pharmacol Ther; 2023 Jul; 114(1):69-76. PubMed ID: 36924260
[TBL] [Abstract][Full Text] [Related]
25. Genes and the response to drugs.
Caraco Y
N Engl J Med; 2004 Dec; 351(27):2867-9. PubMed ID: 15625340
[No Abstract] [Full Text] [Related]
26. Dosing recommendations for pharmacogenetic interactions related to drug metabolism.
Filipski KK; Pacanowski MA; Ramamoorthy A; Feero WG; Freedman AN
Pharmacogenet Genomics; 2016 Jul; 26(7):334-9. PubMed ID: 27058883
[TBL] [Abstract][Full Text] [Related]
27. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.
Thuerauf N; Lunkenheimer J
Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):287-93. PubMed ID: 16783493
[TBL] [Abstract][Full Text] [Related]
28. Update: genetic polymorphism of drug metabolizing enzymes in humans.
Tanaka E
J Clin Pharm Ther; 1999 Oct; 24(5):323-9. PubMed ID: 10583694
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetics-guided dose modifications of antidepressants.
Seeringer A; Kirchheiner J
Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacogenetics or "farm-ecogenetics"?].
Gérard N; Elion J; Krishnamoorthy R
J Soc Biol; 2000; 194(1):9-13. PubMed ID: 11107543
[TBL] [Abstract][Full Text] [Related]
31. [Xenobiotic-metabolizing polymorphic enzymes. An opportunity for individualized drug treatment].
Lhermitte M; Allorge D; Broly F
Bull Acad Natl Med; 2006 Jan; 190(1):55-69; discussion 69-73. PubMed ID: 16878446
[TBL] [Abstract][Full Text] [Related]
32. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.
Nahid NA; Johnson JA
Expert Opin Drug Metab Toxicol; 2022 Nov; 18(11):769-785. PubMed ID: 36597259
[TBL] [Abstract][Full Text] [Related]
33. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital.
Kim YM; Yoo SH; Kang RY; Kim MJ; Bae YY; Lee YK; Jeon SJ; Chon KJ; Shin SM; Kim SG; Park KH; Son IJ
Am J Health Syst Pharm; 2007 Jan; 64(2):166-75. PubMed ID: 17215467
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
Dahl ML
Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
[TBL] [Abstract][Full Text] [Related]
35. Complexities of CYP2D6 gene analysis and interpretation.
Gaedigk A
Int Rev Psychiatry; 2013 Oct; 25(5):534-53. PubMed ID: 24151800
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.
Rogers JF; Nafziger AN; Bertino JS
Am J Med; 2002 Dec; 113(9):746-50. PubMed ID: 12517365
[TBL] [Abstract][Full Text] [Related]
37. CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.
Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
J Psychopharmacol; 2011 Jul; 25(7):908-14. PubMed ID: 20547595
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics of drug-metabolizing enzymes in Italian populations.
Serpe L; Canaparo R; Scordo MG; Spina E
Drug Metab Pers Ther; 2015 Jun; 30(2):107-20. PubMed ID: 25527811
[TBL] [Abstract][Full Text] [Related]
39. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A
OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A; Dorado P; Peñas-Lledó EM
Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
